Surgical Correction of Carcinoid Heart Disease Improves Liver Function and 5-Hydroxyindoleacetic Acid Levels Abstract #2833

Introduction: Neuroendocrine tumours of the gastrointestinal tract cause carcinoid syndrome and carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and valve incompetence. Most cases involve the tricuspid valve +/- pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve replacement surgery which improves exercise tolerance but has high perioperative mortality. We have previously reported that valve-replacement surgery can reduce 5-hydroxyindoleacetic acid (5-HIAA) levels, reflecting a decline in hormone activity.
Aim(s): The purpose of this study is to confirm these findings and investigate the reason for this effect. The liver is known to degrade serotonin and other tumour products; therefore, it is possible that reduction in 5-HIAA is related to improvements in liver function. We investigated the role of the kidneys also.
Materials and methods: Included in this study were all patients from the Queen Elizabeth Hospital Birmingham who had undergone heart-valve replacement surgery from 2010-2019 (n=40). After exclusion criteria were applied, 17 patients were left. We collected tumour markers, liver function data and renal function data pre- and post-surgery using electronic patient records. Data analysis was performed using SPSS.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah

To read results and conclusion, please login ...

Further abstracts you may be interested in

#582 Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours
Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.
Conference:
Category: Clinical
Presenting Author: Dr Rebecca Dobson
#1332 NT-proBNP is Superior to ST2 and Galectin-3 Cardiac Markers in Identifying Carcinoid Heart Disease in Small Bowel NET Patients
Introduction: Carcinoid heart disease (CHD) develops in small bowel neuroendocrine tumour (sbNET) patients with carcinoid syndrome (CS). NT-proBNP (NTP) is suggested as the best current biomarker to screen and monitor for HF from CHD. A number of other markers, such as Galectin-3 (GAL3) and ST2 (or IL-1 R4), have been explored to diagnose and prognosticate in HF but have not been explored in NET patients with CS and CHD.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Ron Basuroy
#1655 A Case Report of Bicaval Stents and Inferior Vena Cava Valve Implantation to Control Carcinoid Symptoms in Order to Safely Allow Surgical Valve Replacement
Introduction: Surgery for severe tricuspid regurgitation (TR) is a high-risk procedure. Therefore transcatheter valve implantation into the vena cava can be performed as an attempt to reduce the complications and symptoms associated with this.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Dr Vandana Sagar
Authors: Sagar V, Steeds R, Doshi S, Shetty S, ...
#1818 Patient Outcomes after Cardiac Surgery for Carcinoid Heart Disease Are Dependant Upon Successful Cytoreductive Multimodal Treatment and Control of Metastatic Neuroendocrine Disease
Introduction: Carcinoid Heart Disease (CHD) as a result of long standing carcinoid syndrome is associated with a poor prognosis due to development of valvular incompetence & right heart failure. Cardiac valve surgery is the main therapeutic option.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: John Knight
Authors: Jaber B, Ramsey E, Cowburn P, Tsang G, ...
#2684 Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection
Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) are steadily increasing in prevalence and present several clinical challenges.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Wuhu Zhang
Authors: Zhang W, Wang W, ...